Abstract: Disclosed are an organometallic compound, more particularly, an organometallic compound having phosphorescent properties, and an organic light-emitting diode containing the same. The organometallic compound is represented by Ir(LA)n(LB)3-n, where n is an integer of 1 to 3, LA is a ligand represented by one of Chemical Formula 1-1, Chemical Formula 1-2, and Chemical Formula 1-3, and LB is a bidentate ligand.

Abstract: Disclosed are an organometallic compound represented by Chemical Formula 1, and an organic light-emitting diode containing the same.

Abstract: A platinum complex comprises a chemical structure of Structure (II): where R3, R4, R5, R6, R7 and RE are independently selected From a hydrogen atom, a substituted or unsubstituted linear or branched chain C1 to C5 alkyl group, a cycloalkyl group, a substituted or unsubstituted aryl group, and a heteroaryl group, R9 and R10 are independently selected from the group consisting of a hydrogen atorn, a substituted or unsubstituted linear or branched chain C1 to C5 alkyl group, a substituted or unsubstituted aryl group, and a carboxyl group; and n is an electrical charge of the complex and is 0, a positive integer or a negative integer.

Abstract: Various embodiments relate to a method for producing a metal-organic framework (MOF) having a desired redox conductivity and including redox-active linkers, having ?-alkyl-ferrocene groups, via de novo solvothermal synthesis. Various embodiments relate to a metal-organic framework (MOF) linker comprising an ?-alkyl-ferrocene group. Various embodiments relate to a metal-organic framework (MOF), having a first plurality of redox-active linkers, each having an ?-alkyl-ferrocene group. The MOF according to various embodiments, may further have one or more redox-inactive linkers. Various embodiments relate to materials, apparatuses, and components that include the MOF according to various embodiments. For example, various embodiments relate to thin-films, bulk powders, or electrodes.

Abstract: The invention relates to a method for recovery and purification of a neutral or sialylated human milk oligosaccharide (HMO) from a fermentation broth, comprising the steps of separating the fermentation broth to form a separated HMO-containing stream and a biomass waste stream, purifying the HMO-containing stream by nanofiltration, purifying the HMO-containing stream with an acidic cation exchange resin, concentrating the purified HMO-containing stream, and drying the purified HMO-containing stream to obtain a solidified neutral or sialylated HMO. Moreover, the invention also concerns a neutral or sialylated human milk oligosaccharide obtained by the inventive method, as well as its use in food, feed, and medical application.

Abstract: Disclosed are a series of deuterated nucleoside compounds and a use thereof. Specifically disclosed are compounds represented by formula (VI-2), and stereoisomers or pharmaceutically acceptable salts thereof.

Abstract: The present invention provides the use of a separation process to obtain a product composition comprising at least one sophorolipid, wherein the product composition achieves a negative result under the h-CLAT assay according to OECD 442E, wherein the separation process comprises removing a protein component from a starting composition comprising said glycolipid to obtain said product composition, wherein said starting composition achieves a positive result under the h-CLAT assay. The invention further provides a process for obtaining a product composition comprising at least one glycolipid, a product composition obtainable from the process and a personal care formulation or home care formulation comprising the product composition.

Abstract: The present disclosure provides a 3-phenoxybenzoic acid-glucuronic acid conjugate, and a preparation method and use thereof, and belongs to the technical field of pesticide detection. Compared with 3-phenoxybenzoic acid, the 3-phenoxybenzoic acid-glucuronic acid conjugate provided by the present disclosure features structural stability, high specificity, long limit of detection, and high content in urine, and can better serve as a marker that identifies whether an organism is killed due to pyrethroid pesticide poisoning. Namely, the 3-phenoxybenzoic acid-glucuronic acid conjugate can detect whether a toxicant (pyrethroid pesticides) is taken antemortem or exposed postmortem, and has an excellent application prospect in pyrethroid pesticide detection. The present disclosure provides a preparation method of a 3-phenoxybenzoic acid-glucuronic acid conjugate.

Abstract: Embodiments of the present application relate to functionalized N-acetylgalactosamine-analogs, methods of making, and uses of the same. In particular, mono or trivalent N-acetylgalactosamine analogs may be prepared by utilizing a wide variety of linkers containing functional groups. These functionalized N-acetylgalactosamine-analogs may be used in the preparation of targeted delivery of oligonucleotide-based therapeutics.

Abstract: Compounds of formula (I), compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described and pharmaceutical compositions comprising at least one such agent are described.

Abstract: D-galactopyranose compound of formula (1) wherein the pyranose ring is ?-D-galactopyranose, and these compounds are high affinity galectin-1 and/or galectin 3 inhibitors for use in treatment of inflammation; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; septic shock; cancer; metastasising cancers; autoimmune diseases, metabolic disorders; heart disease; heart failure; pathological angiogenesis; eye diseases; atherosclerosis; metabolic diseases; diabetes type I; diabetes type II; insulin resistance; Diastolic heart failure; asthma; and liver disorders.

Abstract: Compounds of the Formula (I), pharmaceutical compositions comprising compounds of the Formula (I), and their use for treating or preventing an infection caused by Human Cytomegalovirus (HCMV), Epstein-Barr virus (EBV), or Human Immunodeficiency Virus (HIV):

Abstract: The present invention is directed to prodrugs of compound A: which are nucleoside reverse transcriptase translocation inhibitors (NRTTI) and are useful in the inhibition of HIV reverse transcriptase. The present invention also relates to the use of these compounds for prophylaxis of infection by HIV, treatment of infection by HIV, and prophylaxis, treatment, and delay in the onset or progression of AIDS and/or AIDS-related complexes.

Abstract: 3beta, 17beta disubstituted steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.

Abstract: The invention relates to a synthesis of cholesterol; a ring opening step of the compound of formula (I) and subsequent activation and reduction step yielding cholesterol. The inventions relates also to intermediates achieved during said synthesis.

Abstract: Novel chemical agents are described herein. More specifically, a novel inhibitor of 17?-HSD7 for decreasing estradiol concentrations while restoring dihydrotestosterone (DHT) concentrations in breast cancer cells is disclosed herein. In a particular embodiment, the inhibitor of 17?-HSD7 has the following structure: (Formula I) A process for producing the novel inhibitors of 17?-HSD7 and their use in the manufacture of pharmaceutical formulations and/or combinations is also disclosed.

Abstract: The present disclosure generally relates to the field of solid phase synthesis and methods for synthesizing peptides and employing solid phase synthesis.

Abstract: Synthetic methods are described herein operable to efficiently produce a wide variety of molecular species through conjugate additions via decarboxylative mechanisms. For example, methods of functionalization of peptide residues are described, including selective functionalization of peptide C-terminal residues. In one aspect, a method of peptide functionalization comprises providing a reaction mixture including a Michael acceptor and a peptide and coupling the Michael acceptor with the peptide via a mechanism including decarboxylation of a peptide reside.

Abstract: Provided are a compound for alcoholic liver injury, a preparation method, a composition, a food and the use. The compound has the following formula (I), wherein M is a divalent metal cation selected from Cu, Fe and Zn; A is selected from glutathione and a derivative thereof, and the derivative of glutathione is selected from: at least one of amino or carboxyl in glutathione substituted with an amino protecting group and/or a carboxyl protecting group; B is a monovalent or divalent balance anion; and n is 1 or 2.

Abstract: The present invention provides a peptide having a fluoroalkyl group in the side chain. The present invention provides a peptide in which 2 or more amino acids are peptide-bonded in which at least one side chain of an amino acid residue constituting the peptide is represented by the following General Formula (1) [in the formula, Z1 is a divalent, trivalent, or tetravalent linking group other than an alkylene group; Rf is a C1-30 alkyl group substituted with at least two fluorine atoms, —SF5, or —SF4—CR101R102—CR103R104Cl (R101, R102, R103, and R104 are each independently a hydrogen atom, a fluorine atom, or a chlorine atom, and two or more of R101, R102, R103, and R104 are fluorine atoms); n3 is 1, 2, or 3, and the black circle indicates a bonding site].

Abstract: The present invention addresses the problem of providing a novel peptide which can treat, prevent or ameliorate anorexia. The present invention provides a peptide described in any one of the following items (1) to (3). (1) A peptide consisting of 4 to 9 inclusive contiguous amino acid residues in the amino acid sequence represented by SEQ ID NO: 1; (2) a peptide consisting of 4 to 12 inclusive contiguous amino acid residues in the amino acid sequence represented by SEQ ID NO: 2; and (3) a peptide consisting of an amino acid sequence having 90% or higher identity to the amino acid sequence represented by SEQ ID NO: 2.

Abstract: The present invention relates to a peptide of a novel sequence, having the activities of preventing hair loss and promoting hair growth, the peptide having the activity of promoting or inducing the proliferation or activation of cells related to hair formation, and thus a composition comprising the peptide can be effectively used for preventing hair loss or promoting hair growth.

Abstract: Peptides for use as senotherapeutic agents. The present invention refers to senotherapeutic agents comprising different peptides for use in the prevention or treatment of aging-associated diseases caused by the persistence and accumulation of senescent cells.

Abstract: An antimicrobial peptide (AMP) or peptide derivative, a substitute for the AMP or peptide derivative, an AMP or peptide derivative composition, and a preparation method and application of the AMP or peptide derivative composition. The AMP or peptide derivative includes at least one selected from the group consisting of amino acid sequences I and II: where Xa1, Ba1, U1, Za1, Ba2, Xa2, Ba3, Za2, Ba4, Xa3, Xb1, Bb1, Ca1, Zb1, Bb2, Xb2, Bb3, Zb2, Bb4, Xb3, and Ca2 each are independently selected from the group consisting of natural amino acids (NAAs) and unnatural amino acids (UAAs). The AMP or peptide derivative provided by the present application can combine with a lipid structure of a cell wall/membrane to damage its physical and chemical properties, thereby destroying the microbial wall/membrane to kill microorganisms and tumor cells.

Abstract: The present invention relates to compounds comprising formula I: Amino Acid Sequence-(L)n-DMARD wherein the amino acid sequence comprises QKRAAYDQYGHAAFE-NH2 (SEQ ID NO: 1), DMARD is a disease modifying antirheumatic agent L is a linker unit, —is a covalent bond and n is 0 or 1 and methods of using the compound for treatment of autoimmune diseases. In a preferred embodiment the DMARD is selected from Chloroquine and Hydroxychloroquine.

Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.

Abstract: Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, can inhibit TNFR1 and are expected to have utility as therapeutic agents, for example, for treating inflammatory bowel diseases, rheumatoid arthritis, junvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of inflammatory bowel diseases, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa, and for preparing pharmaceuticals for this purpose.

Abstract: The present invention directed to a novel macrocyclic depsipeptide compound, its derivatives, and their pharmaceutically acceptable salts, having selective antibacterial activity against M. tuberculosis.

Abstract: The invention provides compositions comprising a single protein having one or more biopolymers or modified biopolymers for therapeutics and diagnostics tightly bound therein. The compositions are useful to enhance efficacy and water solution of biopolymers, decrease their toxicity and/or to widen therapeutic window of the biopolymers. The invention also provides methods for preparing such compositions.

Abstract: The disclosure is directed in part to variant capsid polypeptides that can be used to deliver payloads.

Abstract: Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).

Abstract: The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.

Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.

Abstract: The present disclosure provides codon optimized synthetic nucleotide sequences encoding Bacillus thuringiensis (Bt) insecticidal crystal Cry2Ai protein having insecticidal activity against insect pests including, but not limited to insect pests belonging to the order Lepidoptera. The present disclosure also relates to expression of these sequences in plants. The disclosure further provides a DNA construct, a vector, and a host cell comprising the codon optimized synthetic nucleotide sequences of the invention. Also it provides use of the codon optimized synthetic nucleotide sequences for production of insect resistant transgenic plants, and a composition comprising Bacillus thuringiensis comprising the codon optimized synthetic nucleotide sequence of the present invention.

Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.

Abstract: Described herein are cystine-dense peptides capable of binding to PD-L1. Such peptides may function as PD-L1 inhibitors by binding to the PD-1-binding interface of PD-L1 and inhibiting interactions between PD-L1 and PD-1. Methods of using PD-L1-binding peptides to treat cancers, autoimmune diseases, or other conditions are also described herein. Such methods include delivering active agents complexed with a PD-L1-binding peptide to a PD-L1 positive cell or using a bispecific immune cell engager to recruit immune cells to PD-L1 positive cells. Also described herein are chimeric antigen receptors comprising PD-L1-binding peptides.

Abstract: Described in several exemplary embodiments herein are engineered biomolecules that can be capable of nutrient reprogramming in a cell. Also described herein are methods of using the engineered biomolecules.

Abstract: A peptide mixture suitable for eliciting an immune response, comprising a first peptide and a second peptide. The first peptide comprises a first sequence of at least (8) amino acids, wherein said first sequence has at least 75% sequence identity to a first region of (8) amino acids of SEQ ID NO: 11. This first region includes position (201) of the SEQ ID NO: 11 such that the first sequence includes the amino acid in position (201) of the SEQ ID NO: 11. The second peptide comprises a second sequence of at least (8) amino acids, wherein said second sequence has at least 75% sequence identity to a second region of (8) amino acids of SEQ ID NO: 12. This second region includes position (201) of the SEQ ID NO: 12 such that the second sequence includes the amino acid in position (201) of the SEQ ID NO: 12.

Abstract: The technology described herein is directed to engineered polypeptides comprising an anti-GYPA antibody reagent and an EPO polypeptide, such as an EPO polypeptide that is engineered to be tissue-protective. Further provided herein are methods of treating a neurodegenerative disease or disorder, hypoxic tissue damage, traumatic brain injury, or stroke by administering said polypeptides.

Abstract: Disclosed herein are interleukin (IL) 15 conjugates and use in the treatment of one or more indications. Also described herein include pharmaceutical compositions and kits comprising one or more of IL-15 conjugates.

Abstract: A fusion protein of interleukin-2 and human serum albumin. By electroporating a plasmid carrying interleukin-2 and human serum albumin fusion gene into a CHO cell, a CHO monoclonal cell line stably and efficiently expressing a human recombinant protein is obtained. The monoclonal cell line can secrete and express a fusion protein of interleukin-2 and human serum albumin. The fusion protein can prolong the plasma half-life of human interleukin-2, and can be used for preparing human interleukin-2 drugs or drugs for treating various diseases such as tumors and immunodeficiency diseases.

Abstract: Described herein are compositions and methods for treating pulmonary fibrosis and cancer. The compositions include growth hormone releasing hormone peptides. The methods include reducing lung inflammation, lung scarring, reducing expression of T cell receptor complex genes as well as inhibiting tumor growth.

Abstract: Provided herein are melanocortin 3 receptor (MC3R) agonist peptides and methods of use thereof for the treatment and/or prevention of eating disorders (e.g., anorexia nervosa, cachexia, etc.), metabolic disorders (e.g., sarcopenia), endocrine and growth disorders (e.g. delayed growth and/or delayed puberty), and/or emotional/mental disorders (e.g., depression, anxiety, OCD, PTSD, etc.). In particular, provided herein are MC3R agonist peptides that exhibit enhanced selectivity for MC3R over other melanocortin receptors (e.g., melanocortin 4 receptor (MC4R), melanocortin 1 receptor (MC1R), etc.) and/or are MC4R antagonists, and methods of use thereof. MC3R agonist peptides herein may exhibit enhanced in vitro potency, in vivo efficacy and pharmacokinetic properties compared to other know MC3R agonists.

Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin and comprises an open reading frame encoding a chain of a T cell receptor or of an artificial T cell receptor. Such RNA replicons are useful for expressing a T cell receptor or an artificial T cell receptor in a cell, in particular an immune effector cell such as a T cell. Cells engineered to express such T cell receptor or artificial T cell receptor are useful in the treatment of diseases characterized by expression of antigens bound by the T cell receptor or artificial T cell receptor.

Abstract: The present invention relates to the field of immunotherapy, in particular, of cancer, more specifically, to adoptive T cell therapy or T cell receptor (TCR) gene therapy directed to an epitope derived from the cancer-testis antigen MAGEA4 presented on HLA-A*01, in particular, the immunodominant epitope of SEQ ID NO: 1. The invention provides a nucleic acid encoding a TCR alpha chain construct (TRA) and/or a TCR beta chain construct (TRB) of a TCR construct, wherein the TCR construct is capable of specifically binding to said epitope in the context of HLA-A*01. Proteins encoded by said nucleic acids, corresponding host cells and pharmaceutical compositions, e.g., for use in treating cancer such as melanoma, gastric cancer, head and neck, lung, breast, ovarian, bladder, and esophageal cancer, are also objects of the invention. In another aspect, the invention provides specific peptides comprising said epitopes, and pharmaceutical compositions comprising the same, e.g., for use in vaccination.

Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Abstract: The present disclosure provides pharmaceutical compositions of a chimeric protein comprising a factor VIII (FVIII) polypeptide and a von Willebrand factor (VWF) polypeptide. Also disclosed are pharmaceutical kits and methods of using the disclosed pharmaceutical compositions to treat hemophilia A.

Abstract: The present invention relates to an improved method of quantification and/or estimation of purity of antibody or fusion protein from a protein mixture containing impurity by providing long term sample stability. The invention provides a stable protein solution comprising antibody having reduce formation of Fab and Fc related impurities.

Abstract: The present disclosure is directed to an antibody cocktail comprising antibodies that bind to and protect subjects again multiple ebolavirus strains and methods for use thereof.

Abstract: Provided is a human antibody against a spike protein of coronavirus, in particular, against a protein in an extracellular region or a receptor-binding domain.